Ömer AYTEN, Dilaver TAŞ, Osman Metin İPÇİOĞLU, Oğuzhan OKUTAN, Zafer KARTALOĞLU, Ersin DEMİRER

MALİGN VE PARAPNOMONİK EFÜZYON AYRIMINDA PLEVRAL SIVI CREAKTİF PROTEİN VE KARSİNOEMBRİYONİK ANTİJEN DÜZEYLERİNİN TANISAL DEĞERİ

Amaç: Biz bu çalışmamızda plevral sıvı karsinoembriyonik antijen CEA ve C – reaktif protein CRP seviyelerinin MPE ve PPE ayrımında ki tanısal değerini araştırdık Hastalar ve Yöntem:28 MPE ve 21 PPE hastası çalışmaya dahil edildi. Plevral sıvı CEA ve CRP seviyeleri ölçüldü. Bulgular: MPE ve PPE hastalarında plevral sıvı CEA seviyeleri sırasıyla 55.03±102.96 ng/mL 0.4-387 ve 1.11±1.07 ng/mL 0.12-4.30 ölçüldü. MPE hastalarında yüksek CEA seviyeleri istatistiksel olarak anlamlı idi p

Diagnostic Value of Carcinoembryonic Antigen and C-Reactive Protein Levels In The Discrimination Between Malignant Pleural Effusion and Parapneumonic Effusion

Introduction: There are problems in the differential diagnosis of malignant pleural effusion MPE and parapneumonic effusion PPE . We investigated the diagnostic value of levels of carcinoembryonic antigen CEA and C-reactive protein CRP in the discrimination of MPE and PPE. Materials and Methods: Twenty-eight patients with MPE and 21 patients with PPE were assessed. CEA and CRP levels were measured in the pleural fluids.Results: CEA levels in the pleural fluid were 55.03±102.96 ng/mL and 1.11±1.07 ng/mL 0.12-4.30 in patients with MPE and PPE, respectively. The high levels of CEA in patients with MPE were statistically significant p

Keywords:

malignant pleural effusion, parapneumonic effusion, CEA, CRP,

PDF

___

Light RW. Tumor Markers in Undiagnosed Pleural Effusions. Chest 2004, 126; 1721-1722.

Wrightson JM, Davies RJ. The approach to the patient with a parapneumonic effusion Semin Respir Crit Care Med.2010; 31: 706-715.

Koegelenberg CFN, Diacon AH, Bolliger CT. Parapneumonic pleural effusion and empyema. Respiration 2008; 75: 241-250.

Gaspar MJ, De Miguel J, Garcia Diaz JD, Diez M. Clinical utility of a combination of tumor markers in the diagnosis of malignant pleural effusions. Anticancer Res. 2008; 28: 2947-2952.

Cobanoglu U, Sayir F, Mergan D. Reactive oxygen metabolites can be used to differantiate malignant and non-malignant pleural effusions. Ann Thorac Med. 2010; 5: 140-144.

Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A, et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions Respir Med. 2007; 101: 910-918.

McGrath EE, Warriner D, Anderson PB. The use of non-routine pleural fluid analysis in the diagnosis of pleural effusion Respir Med. 2010; 104: 1092-1100.

Boucher D, Cournoyer D, Stanners CP, Fuks A. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res. 1989; 49: 847-852.

Chen SC, Chen W, Hsu WH, Yu YH, Shih CM. Role of pleural fluid C-reactive protein concentration in discriminating uncomplicated parapneumonic pleural effusions from complicated parapneumonic effusion and empyema. Lung 2006; 184: 141-145.

Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-Gonzalez A, Martinez- Iribarren A, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J. 2009; 34: 1383-1389.

Antony VB, Jantz MA. Primum non nocere and malignant pleural effusions. Respiration 2004; 71: 549-550.

Na MJ, Dikensoy O, Light RW. New trends in the diagnosis and treatment in parapneumonic effusion and empyema. Tuberk Toraks 2008; 56: 113-120.

Hwa Lee J, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron- specific enolase, and cytokeratine 19 fragments in patients with effusions from primary lung cancer. Chest 2005;128:2298–2303.

Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest, 2004;126:1757-1763.

Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, et al. Diagnostic utility of CYFRA 21–1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86:1488–1495.

Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 72–4, carcinoembryonic antigen, CA 15–3, and CA 19–9 assay in pleural fluid: a study of 207 patients. Cancer 1996; 78:736–740.

Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J. 2012; 53: 111-117.

Haider DG, Leuchten N, Schaller G, Yu YH, Shih CM. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006; 146: 533-539.

Farah R, Makhoul N. Usefulnes of various inflammatory markers to differentiate pulmonary edema from pneumonia. IMAJ 2011; 13: 225-229.

Hohenthal U, Hurme S, Helenius H, M, Meurman O,Nikoskelainen J, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009; 15: 1026-1032.

Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28: 2719-2726.

Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-170.

Garcia-Pachon E, Llorca I. Diagnostic value of C-reactive protein in exudative pleural effusions Eur J Intern Med. 2002; 13: 246-249.

Yilmaz Turay U, Yildirim Z, Turkoz Y, Biber C, Erdogan Y, Keyf AI, et al. Use of pleural fluid C-reactive protein in diagnosis of pleural effusions. Respir Med 2000; 94: 432–435.